Mark Layden, PharmD, MBA shares the place in therapy for hypoxia-inducible factor prolyl hydroxylase inhibitors and other general approaches to anemia management in chronic kidney disease. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.